Healthcare / Medical DevicesNasdaqCM
$1.47
-0.41 (-21.81%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-5.2M · quality 48.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
18/100
F
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$2M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-71.4%
↓Gross Margin
44.0%
↓Debt/Equity
0.78
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2011–2024 · 13 años de histórico normalizado
Revenue CAGR
+41.5%
FCF CAGR
—
FCF margin
-48.3%
FCF / Net income
0.35x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $6.5M · net income $-9.1M · FCF $-3.2M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||||||
| Revenue | $6.5M | $6.5M | $3.0M | $822196.00 | $4.2M | $1.0M | $1.5M | $494375.00 | $282145.00 | $50901.00 | $11689.00 | $16588.00 | $27063.00 | $56377.00 | $71503.00 |
| Net Income | $-9.1M | $-9.1M | $-8.0M | $-10.9M | $-6.7M | $-8.3M | $-2.2M | $-3.1M | $-702163.00 | $-2.1M | $-5.0M | $-1.7M | $-760679.00 | $-666454.00 | $-797471.00 |
| EBITDA | $-7.1M | $-7.1M | $-6.9M | $-10.8M | $-5.2M | $-5.5M | $-1.8M | $-2.6M | $-637611.00 | $-2.1M | $-589441.00 | $-1.7M | $-593723.00 | $-540789.00 | $-681773.00 |
| EPS | -3622.80 | -3622.80 | -4644.28 | -25811.64 | -16074.73 | -43776.00 | -12960.00 | -576.00 | 0.00 | -576.00 | -1152.00 | -576.00 | -288.00 | -288.00 | -288.00 |
| Gross Margin | 44.0% | 44.0% | 36.0% | -3.5% | 96.5% | 91.4% | 90.6% | 81.7% | 81.6% | 70.3% | 33.2% | 53.7% | 60.9% | 63.0% | 74.9% |
| Operating Margin | -116.6% | -116.6% | -224.0% | -1292.5% | -125.4% | -531.7% | -120.8% | -532.8% | -227.0% | -4146.1% | -5090.9% | -10131.3% | -2236.4% | -979.7% | -983.4% |
| Net Margin | -139.3% | -139.3% | -266.0% | -1324.8% | -160.0% | -804.7% | -146.4% | -622.2% | -248.9% | -4173.3% | -42426.6% | -10444.1% | -2810.8% | -1182.1% | -1115.3% |
| Balance Sheet | |||||||||||||||
| Debt/Equity | 0.78 | 0.78 | 7.06 | -2.32 | 0.29 | — | — | — | — | — | — | — | — | — | — |
| Current Ratio | 0.12 | 0.12 | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Cash Flow | |||||||||||||||
| Free Cash Flow | $-3.2M | $-3.2M | $-5.2M | $-6.6M | $-6.5M | $-4.8M | $1.3M | $-672371.00 | $-181270.00 | $-339600.00 | $-151622.00 | — | — | — | — |
| Returns | |||||||||||||||
| ROE | -71.4% | -71.4% | -900.1% | 1114.2% | -91.0% | -145.3% | 58.4% | 112.9% | 14.1% | 46.0% | 132.0% | 39.7% | 19.9% | 19.8% | 27.3% |
| Valuation | |||||||||||||||
| P/B | 0.00 | 0.00 | 3.40 | — | 5.69 | — | — | — | — | — | — | — | — | — | — |
| Growth & Yield | |||||||||||||||
| Revenue Growth | 116.3% | 116.3% | 267.4% | -80.2% | — | -29.9% | 199.4% | 75.2% | 454.3% | 335.5% | -29.5% | -38.7% | -52.0% | -21.2% | — |
| EPS Growth | 22.0% | 22.0% | 82.0% | -60.6% | — | -237.8% | -2150.0% | — | 100.0% | 50.0% | -100.0% | -100.0% | 0.0% | 0.0% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-99.3%
Start / end P/E
n/dx → n/dx
EPS bridge
-4644.28 → -3622.80
Residual
-99.3%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.